OBJECTIVE： To observe clinical efficacy and safety of carthamin yellow pigment combined with urinary kallidinogenase in the treatment of acute cerebral infarction. METHODS： 170 patients with acute cerebral infarction were randomly divided into observation group and control group with 85 cases in each group. Both groups received routine treatment of reducing blood pressure， regulating blood lipid， controlling blood glucose， correcting electrolyte disturbances， nourishing and protecting nerve， reducing intracranial pressure， etc. Control group was additionally given Carthamin yellow pigment injection 100 mg added into 250 ml 0.9％ Sodium chloride injection， ivgtt， qd； observation group was additionally given Urinary kallidinogenase injection 0.15 PNA added into 250 ml 0.9％ Sodium chloride injection， ivgtt， qd， on the basis of control group. Both groups received 2 courses of  treatment. Clinical efficacy of 2 groups was observed in 2 groups， and NIHSS and MRS were also observed before and after treatment evalnation of neurological deficits and disability； blood routine， 4 blood coagulation items， hepatic and liver function  were compared between 2 groups before and after treatment. RESULTS： Total effective rate of observation group was 90.6％， which was significantly higher than 63.5％ of control group， with statistical significance （P＜0.05）. After treatment， NIHSS and MRS of 2 groups decreased significantly， and the observation group was lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in blood routine， 4 blood coagulation items， hepatic and liver function between 2 groups before and after treatment （P＞0.05）. No erythra and electrocardiographic abnormality and other ADRs was observed in 2 groups. CONCLUSIONS： Carthamin yellow pigment combined with urinary kallidinogenase shows obvious therapeutic efficacy and good safety in the treatment of acute cerebral infarction improve the degree of neurological deficits and the degree of disability.